Info

Senesco Technologies, Inc. is a development-stage company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing eucaryotic translation initiation Factor 5A and deoxyhypusine synthase (DHS), in human health applications to develop approaches to treat inflammatory and / apoptotic-related diseases in humans, approaches to treat cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants. On September 11, 2007 it entered into a license agreement with Bayer CropScience AG for the development and commercialization of rice.(Source: 10-K)